好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Folic Acid in Pregnancy and Neuropsychological Outcomes at Age 6-Years-Old in the MONEAD Study
Child Neurology and Developmental Neurology
S31 - Hot Topics in Child Neurology (4:18 PM-4:30 PM)
005
Folic acid supplementation in pregnancy is known to reduce malformations and improve cognitive outcomes, but concerns have been raised over risks of higher folate doses.
To assess the relation of folic acid supplementation during pregnancy and neuropsychological outcomes at age 6-years-old in children of women with epilepsy (WWE) and healthy women (HW).
The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study is a prospective, observational, multi-center investigation which enrolled WWE and HW during pregnancy. The a priori primary neurodevelopmental outcome for children is age 6 Verbal Index score (VIS) calculated by averaging Differential Ability Scales-II Word Definitions and Verbal Similarities subtests, Expressive One-Word Picture Vocabulary Test-4, Peabody Picture Vocabulary Test-4, and Neuropsychological Assessment-2 Phonological Processing, Comprehension of Instructions, and Sentence Repetition subtests. The main behavioral outcome is the Adaptive Behavior Assessment System (ABAS-3) General Adaptive Composite Standard Score. We compared the outcomes in children as a function of folate supplementation using linear regression adjusting for potential confounders chosen via a stepwise selection algorithm. 

Analyses include 345 children of WWE and HW. Adjusted LS Means (95% CI) for children’s VIS were higher in those using folic acid in the first 12 weeks of pregnancy (107.5 (106.5, 108.5)) vs. not (95.8 (86.8, 104.8)), p=0.012. Similarly, adjusted LS Means (95% CI) for ABAS-3 were higher when folic acid was used the first 12 weeks of pregnancy (102.4 (101.3, 103.4)) vs. not (82.2 (73.9, 90.5)), p<0.001. Outcomes were similar for low dose folic acid (>0-0.4mg/day) and high dose (>4.0mg/day) for VIS (109.8 (104.7, 114.9) vs. 108.1 (105.9, 110.3)) and for ABAS-3 (102.5 (97.3, 107.8) vs. 102.7 (100.4, 105.1)).
Folic acid early in pregnancy was associated with improved verbal abilities and adaptive behavior of children at age 6-years-old. No risk of higher doses was apparent in this cohort.
Authors/Disclosures
Kimford J. Meador, MD, FAAN (Stanford University School of Medicine)
PRESENTER 		The institution of Dr. Meador has received research support from NIH. The institution of Dr. Meador has received research support from Eisai. The institution of Dr. Meador has received research support from Medtronics. The institution of Dr. Meador has received research support from The Epilepsy Consortium.
Morris Cohen (Pediatric Neuropsychology International) Morris Cohen has received research support from Stanford University. Morris Cohen has received publishing royalties from a publication relating to health care.
David W. Loring, PhD, FAAN (Emory Univ, Dept of Neurology) Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE. The institution of Dr. Loring has received research support from NIH. Dr. Loring has received publishing royalties from a publication relating to health care.
Abigail Matthews (The Emmes Company, LLC) No disclosure on file
Page B. Pennell, MD, FAAN (University of Pittsburgh School of Medicine) The institution of Dr. Pennell has received research support from NIH. Dr. Pennell has received publishing royalties from a publication relating to health care.